Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS

China’s coronavirus vaccines are leaping ahead – but face challenges as virus wanes

Companies could struggle to enrol enough trial participants, or gather enough data to convince regulatory agencies that the shots work.
  1. David Cyranoski

    1. David Cyranoski reports for Nature from Shanghai, China.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Chinese companies are at the forefront of global efforts to create a vaccine for the coronavirus, with more than half a dozen candidates in clinical development. Last week, Tianjin-based CanSino Biologics published results1 from an early-stage clinical trial showing that its vaccine is safe and can trigger an immune response.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 584, 17-18 (2020)

doi: https://doi.org/10.1038/d41586-020-02244-1

References

  1. Zhu, F.-C. et al. Lancet https://doi.org/10.1016/S0140-6736(20)31605-6 (2020).

    Article  Google Scholar 

  2. Liu, L. et al. JCI Insight 4, e123158 (2019).

    Article  Google Scholar 

  3. Folegatti, P. M. et al. Lancet https://doi.org/10.1016/S0140-6736(20)31604-4 (2020).

    Article  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links